DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2fsjtv/beyondthepill) has announced the addition of the "Beyond-the-Pill Services and Solutions: Pharma's Next Frontier?" report to their offering.
In this report, we look at beyond-the-pill services used by pharma companies including what's driving their use, and the barriers they face. It is important for you to know exactly how this is affecting market access across the pharmaceutical industry so you're able to keep up with the newest trends and stay one step ahead of your competitors.
Payers and governments are striving toward cost-effective treatment outcomes and more efficient care, and waves of new digital health technologies are offering patients unprecedented opportunities to be more engaged in their own health management. Competition, both generic and innovator, is fierce in many chronic disease areas, and is intensified by continued pricing pressure. All of these forces are compelling pharmaceutical firms to not only deliver pills and injections, but to also consider offering services and solutions that support the appropriate use of such medicines.
These services go beyond the traditional adherence programs of the last couple of decades. They increasingly involve technologies and tools designed to influence lifestyle choices and gather physician-relevant data and real-world evidence that may direct future R&D. Many are built around partnerships with consumer-facing technology firms, governments, and payers to map out treatment gaps and improve patient access. Significantly, not all such tie-ups are directly linked to a particular brand or product.
These partnerships are mostly still experimental. They have the potential to redefine pharma's role in the healthcare system, although what that role should be is unclear. There are regulatory, cultural, and business hurdles to engaging more proactively with consumers, healthcare providers, and payers, yet failing to do so will allow newer, non-pharma players to seize more of the patient-centric healthcare pie, leaving pharma with less control over their products' outcomes, ultimately presenting even more of a challenge.
What's included in this report?
- An overview of beyond-the-pill services used by pharma companies including drivers and resistors of their use
- Analysis of the variety of beyond-the-pill services pharma companies have developed in order to engage different stakeholders
- Case study analysis of past and present beyond-the-pill services
- Barriers to pharma's wider use of beyond-the-pill services
Features and Benefits:
- Understand how pharma is experimenting with beyond-the-pill services and why
- Gain insight into which beyond-the-pill service models have been used so far
- Inform your beyond-the-pill service strategy by understanding your competitors' experience with such services
We'll answer these key questions:
- When should pharma companies consider beyond-the-pill services?
- What are the key challenges encountered when engaging in beyond-the-pill services?
- What corporate and cultural obstacles need to be overcome to successfully design and deliver a beyond-the-pill service?
Key Topics Covered:
1. Executive Summary
- Outcomes focus drives pharma to look at wrap-around services
- Pharma companies are exploring a range of beyond-the-pill solutions
- Product-to-services transition demands strategic and cultural change
2. Why Pharma is Looking at Wrap-Around Services
- A range of forces is compelling pharma to look at beyond-the-pill services and solutions
- Beyond-the-pill programs remain experimental
- Bibliography
3. Pharma is Trialing Various Beyond-the-Pill Models
- Focus is on chronic diseases, often with partners
- Selected beyond-the-pill programs illustrate the range of approaches and partnerships
- Bibliography
4. Beyond-the-Pill Case Studies Illustrate Challenges and Opportunities
- AstraZeneca - Me&MyCOPD
- Novartis - Living Like You & SymTrac online MS community
- Novartis - Mobile Eye Unit Partnership with NHS
- Novo Nordisk - Cities Changing Diabetes
- Johnson & Johnson - Care4Today NHS Partnership
- Sanofi/Medtronic - Drug-device combos and services
- Merck & Co - Vree Health subsidiary
- Bibliography
5. Shift to Services Demands Strategic and Cultural Changes
- Pharma needs to use beyond-the-pill solutions only when necessary as commercial returns remain uncertain
- Corporate culture must change
- Multidisciplinary and cross-company collaboration
- Bibliography
6. Appendix
For more information visit http://www.researchandmarkets.com/research/2fsjtv/beyondthepill
